Skip to main content
    N

    Nuvectis Pharma Inc (NVCT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $19.20
    +0.09 (+0.47%)

    Market Cap: $696.03M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Nuvectis Pharma Inc (NVCT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Nuvectis Pharma (NVCT) has a market cap of $696.03M and an enterprise value of $555.32M. Its share count is up 29.70% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 20.22% below the market cap, as cash exceeds debt.

    Market Cap$696.03M
    Enterprise Value$555.32M
    Latest price (Nov 17, 2026)$19.20

    Key Dates

    The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 9, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 25.52% in the quarter ended Sep 30, 2026 and grew 30.77% a year over 2 years.

    Shares Outstanding29.47M
    Shares Change (YoY)+29.70%
    Shares Change (QoQ)+25.52%
    Share Count Growth (2Y CAGR)+30.77%

    Price Statistics

    The stock is up 218.94% over 52 weeks and trades 5.88% below its 50-day average.

    Beta (1Y)0.81
    52-Week Change+218.94%
    1-Month Change+1.37%
    3-Month Change-17.70%
    6-Month Change+86.41%
    Total Return (1Y)+218.94%
    Total Return (3Y CAGR)+32.78%
    Return vs SPY (1Y)+205.80%
    Max Drawdown (1Y)-37.75%
    Max Drawdown (3Y)-58.91%
    Sharpe Ratio (1Y)1.33
    Correlation with SPY (1Y)0.13
    50-Day Average$20.40
    200-Day Average$15.29
    52-Week Range$5.77 to $29.27
    RSI (14 Days)45.9
    Average Volume (20 Days)214.77K

    Price chart

    Financial Position

    Current assets cover 9.92x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio9.92x
    Quick Ratio9.92x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -39.84% and return on assets is -35.82% over the last 12 months.

    Return on Equity (ROE)-39.84%
    Return on Assets (ROA)-35.82%

    Scores

    NVCT has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Operating Income-$52.12M
    Pretax Income-$50.45M
    Net Income-$50.45M
    Reported EPS (TTM)-$1.89

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 89.92% of the $140.84M in total assets.

    Cash and Equivalents$140.71M
    Total Debt$0
    Net Cash$140.71M
    Net Cash Per Share$4.78
    Working Capital$126.65M
    Shareholder Equity$126.65M
    Book Value Per Share$4.30
    Total Assets$140.84M
    Total Liabilities$14.19M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$40.29M
    FCF Per Share-$1.23
    Share Repurchases$9.49M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+9.78%
    Tangible Book Per Share Growth (2Y CAGR)+9.78%

    Revenue and profit by year

    Dividends and Yields

    NVCT does not pay a dividend.

    Buyback Yield-25.70%
    Shareholder Yield-25.70%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About NVCT

    What is NVCT's market cap?

    Nuvectis Pharma has a market cap of $696.03M. Its enterprise value, which adds debt and subtracts cash, is $555.32M.

    How many shares of NVCT are outstanding?

    Nuvectis Pharma has 29.47M shares outstanding. The count is up 29.70% from a year earlier.

    Does NVCT pay a dividend?

    No. Nuvectis Pharma does not pay a dividend.

    How much debt does NVCT have?

    Nuvectis Pharma has $0 of total debt and $140.71M of cash and equivalents, a net cash position of $140.71M.